57
Participants
Start Date
May 27, 2015
Primary Completion Date
April 9, 2026
Study Completion Date
April 9, 2026
Ceritinib (LDK378)
Nivolumab
Novartis Investigative Site, Leuven
Novartis Investigative Site, Heidelberg
Fox Chase Cancer Center, Philadelphia
Novartis Investigative Site, Milan
Novartis Investigative Site, Modena
Mayo Clinic - Arizona, Scottsdale
Novartis Investigative Site, Singapore
Novartis Investigative Site, Hong Kong
Massachusetts General Hospital, Boston
Massachusetts General Hospital Thoracic Oncolgoy, Boston
Novartis Investigative Site, Toronto
Novartis Investigative Site, Barcelona
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY